Brett Hanscom

Infectious Disease Research Institute — United States

Medicine · Health Sciences

33h-index9.2kcitations103works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(44), HIV Research and Treatment(32), HIV, Drug Use, Sexual Risk(28), Musculoskeletal pain and rehabilitation(27), Spine and Intervertebral Disc Pathology(24)

Publications102 total

Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083
The Journal of Infectious Diseases·2025Open Access
Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084
Journal of the International AIDS Society·2025Open Access
Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis
Journal of the International AIDS Society·2025· 2 citedOpen Access
Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083
Clinical Infectious Diseases·2025Open Access
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial
The Lancet HIV·2025· 4 citedOpen Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
UNC Libraries·2025Open Access
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
BMC Immunology·2025· 3 citedOpen Access
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
UNC Libraries·2025Open Access
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
UNC Libraries·2025· 1 citedOpen Access
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
UNC Libraries·2025Open Access
Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084
Journal of the International AIDS Society·2025· 10 citedOpen Access
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
The Lancet HIV·2024· 7 citedOpen Access
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
Clinical Infectious Diseases·2024Open Access
Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084
Antimicrobial Agents and Chemotherapy·2024· 2 citedOpen Access
Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study)
Trials·2024· 9 citedOpen Access
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084
AIDS Research and Human Retroviruses·2024· 2 citedOpen Access
Immunogenicity and Safety of Meningococcal ACWYX Conjugate Vaccine When Coadministered with Routine Childhood Vaccines at 9-Months and 15-Months of Age: A Randomised, Controlled, Phase 3, Non-Inferiority Trial
SSRN Electronic Journal·2024Open Access
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084
UNC Libraries·2023Open Access
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
UNC Libraries·2023Open Access
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
UNC Libraries·2023Open Access
page 1 of 6Next →

Frequent Co-authors

James N. Weinstein(14), Jon D. Lurie(11), Susan H. Eshleman(10), Deborah Donnell(9), Estelle Piwowar‐Manning(9), William A. Abdu(8), Tor D. Tosteson(7), Mark A. Marzinke(7), James F. Rooney(7), Alex R. Rinehart(7), Adeola Adeyeye(7), Myron S. Cohen(7), Todd J. Albert(6), Alan S. Hilibrand(6), Raphael J. Landovitz(6), Craig W. Hendrix(6), Peter L. Anderson(6), Ryan Kofron(6), Beatriz Grinsztejn(6), Anna N.A. Tosteson(5)